Henrique Tria Bianco

Henrique Tria Bianco

Auto-generated profile, based on publicly available information

Henrique Tria Bianco

Federal University of São Paulo

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Circulation Journal
Verified
Journal Article
Open access
PDF file
CFCarolina Nunes França
Carolina Nunes França
LPLuiz F.M. Pinheiro
Luiz F.M. Pinheiro
MIMaria C.O. Izar
Maria C.O. Izar
MBMilena Karina Coló Brunialti
Milena Karina Coló Brunialti
RSReinaldo Salomao
Reinaldo Salomao
FFFrancisco Antonio Antonio Helfenstein Helfenstein Fonseca
Francisco Antonio Antonio Helfenstein Helfenstein Fonseca
Background: Increased numbers of endothelial (EMP) and platelet (PMP) microparticles have been related to cardiovascular risk factors and coronary artery disease. Little is known about the early effects of statins and clopidogrel on these new biomarkers of vascular homeostasis. The aim of the present study was to evaluate pharmacokinetic interactions between atorvastatin and clopidogrel and their effects, alone or combined, on EMP, PMP, and endothelial progenitor cells (EPC). Methods and Results: A prospective open-label study enrolled subjects with stable coronary disease (n=26). Drugs were given daily for 3 weeks (atorvastatin 80mg, visits 1-3; clopidogrel 75mg, visits 2-4). Counts of EPC (CD34+/CD133+/KDR+), EMP (CD51+) and PMP (CD42+/CD31+), and pharmacokinetic parameters over 24h were assessed at each visit. Atorvastatin plasma concentrations were increased by concomitant therapy with clopidogrel (maximum serum concentration [Cmax], P=0.002; area under the clopidogrel or atorvastatin plasma concentration vs. time curve from 0 to the last detectable concentration [AUClast], P=0.03). After atorvastatin withdrawal there was an increase in clopidogrel plasma concentrations (Cmax, P=0.009; AUClast, P=0.039). PMP were inversely correlated with clopidogrel Cmax on visit 3 (rho=-0.57, P=0.006) and on visit 4 (rho=-0.54, P=0.01), and with clopidogrel AUClast on visit 3 (rho=-0.44, P=0.04), and on visit 4 (rho=-0.57, P=0.005). In addition, clopidogrel Cmax was correlated with EPC (CD133+/KDR+) on visit 4 (rho=0.48, P=0.025). No correlations of atorvastatin and MP or EPC were found. Conclusions: The balance between platelet MP release and EPC mobilization seems influenced by clopidogrel plasma levels, suggesting a protective mechanism on coronary artery disease. (Circ J 2012; 76: 729-736)

14 July 2017 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MBMarcello Casaccia Bertoluci
Marcello Casaccia Bertoluci
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
AFAndré Faludi
André Faludi
Maria Cristina IzarMaria Cristina Izar
Maria Cristina Izar
BSBeatriz Schaan
Beatriz Schaan
RSRaul D Santos
Raul D Santos
Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes. The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy. Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.

1 June 2012 in International Journal of Cardiology
Verified
Journal Article
Closed access
LPLuiz F. Pinheiro
Luiz F. Pinheiro
CFCarolina N. França
Carolina N. França
MIMaria C. Izar
Maria C. Izar
SBSimone P. Barbosa
Simone P. Barbosa
HBHenrique T. Bianco
Henrique T. Bianco
FFFrancisco Antonio Antonio Helfenstein Helfenstein Fonseca
Francisco Antonio Antonio Helfenstein Helfenstein Fonseca

15 April 2014 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
LCL.M. Camargo
L.M. Camargo
CFCarolina Nunes França
Carolina Nunes França
MIM.C. Izar
M.C. Izar
HBH.T. Bianco
H.T. Bianco
LLL.S. Lins
L.S. Lins
FFFrancisco Antonio Antonio Helfenstein Helfenstein Fonseca
Francisco Antonio Antonio Helfenstein Helfenstein Fonseca
It is not known whether the addition of ezetimibe to statins adds cardiovascular protection beyond the expected changes in lipid levels. Subjects with coronary heart disease were treated with four consecutive 1-week courses of therapy (T) and evaluations. The courses were: T1, 100 mg aspirin alone; T2, 100 mg aspirin and 40 mg simvastatin/10 mg ezetimibe; T3, 40 mg simvastatin/10 mg ezetimibe, and 75 mg clopidogrel (300 mg initial loading dose); T4, 75 mg clopidogrel alone. Platelet aggregation was examined in whole blood. Endothelial microparticles (CD51), platelet microparticles (CD42/CD31), and endothelial progenitor cells (CD34/CD133; CDKDR/CD133, or CD34/KDR) were quantified by flow cytometry. Endothelial function was examined by flow-mediated dilation. Comparisons between therapies revealed differences in lipids (T2 and T3<T1 and T4 for total cholesterol, LDL-C, and triglycerides; PT1 and T4, P=0.001). Decreased platelet aggregation was observed after aspirin (arachidonic acid, T1<T3 and T4, P=0.034) and clopidogrel (adenosine, T3 and T4<T1 and T2, P<0.0001) therapy. Simvastatin/ezetimibe diphosphate did not change platelet aggregation, the amount of circulating endothelial and platelet microparticles, or endothelial progenitor cells. Cardiovascular protection following therapy with simvastatin/ezetimibe seems restricted to lipid changes and improvement of endothelial function not affecting the release of microparticles, mobilization of endothelial progenitor cells or decreased platelet aggregation.

19 December 2017 in Trials
Verified
Journal Article
Open access
PDF file
FIfor the BATTLE-AMI Investigators
for the BATTLE-AMI Investigators
FFFrancisco Antonio Antonio Helfenstein Helfenstein Fonseca
Francisco Antonio Antonio Helfenstein Helfenstein Fonseca
Maria Cristina IzarMaria Cristina Izar
Maria Cristina Izar
IMIeda M. L. Maugeri
Ieda M. L. Maugeri
OBOtavio Berwanger
Otavio Berwanger
ACAntonio C. C. Carvalho
Antonio C. C. Carvalho
Early reperfusion of the occluded coronary artery during acute myocardial infarction is considered crucial for reduction of infarcted mass and recovery of ventricular function. Effective microcirculation and the balance between protective and harmful lymphocytes may have roles in reperfusion injury and may affect final ventricular remodeling. BATTLE-AMI is an open-label, randomized trial comparing the effects of four therapeutic strategies (rosuvastatin/ticagrelor, rosuvastatin/clopidogrel, simvastatin plus ezetimibe/ticagrelor, or simvastatin plus ezetimibe/clopidogrel) on infarcted mass and left ventricular ejection fraction (LVEF) (blinded endpoints) in patients with ST-segment elevation myocardial infarction submitted to fibrinolytic therapy before coronary angiogram (pharmacoinvasive strategy). All patients (n = 300, 75 per arm) will be followed up for six months. The effects of treatment on subsets of B and T lymphocytes will be determined by flow-cytometry/ELISPOT and will be correlated with the infarcted mass, LVEF, and microcirculation perfusion obtained by cardiac magnetic resonance imaging. The primary hypothesis is that the combined rosuvastatin/ticagrelor therapy will be superior to other therapies (particularly for the comparison with simvastatin plus ezetimibe/clopidogrel) for the achievement of better LVEF at 30 days (primary endpoint) and smaller infarcted mass (secondary endpoint) at 30 days and six months. The trial will also evaluate the improvement in the immune/inflammatory responses mediated by B and T lymphocytes. Omics field (metabolomics and proteomics) will help to understand these responses by molecular events. BATTLE-AMI is aimed to (1) evaluate the role of subsets of lymphocytes on microcirculation improvement and (2) show how the choice of statin/antiplatelet therapy may affect cardiac remodeling after acute myocardial infarction with ST elevation. ClinicalTrials.gov, NCT02428374 . Registered on 28 September 2014.

1 May 2013 in Life Sciences
Verified
Journal Article
Closed access
SBSimone P. Barbosa
Simone P. Barbosa
LLLívia C. Lins
Lívia C. Lins
FFFrancisco A. Fonseca
Francisco A. Fonseca
LMLívia N. Matos
Lívia N. Matos
AAAna C. Aguirre
Ana C. Aguirre
Maria Cristina IzarMaria Cristina Izar
Maria Cristina Izar